We can’t show the full text here under this license. Use the link below to read it at the source.
Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin
Time until stronger treatment is needed with GLP-1 drugs versus other medicines in people with type 2 diabetes on metformin
AI simplified
Abstract
A total of 59,958 participants were included, with GLP-1 receptor agonists (GLP-1RAs) linked to a lower rate of treatment intensification than other glucose-lowering medications.
- Initiation of GLP-1RA treatment was associated with a reduced need for a subsequent glucose-lowering medication compared to SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas.
- The hazard ratios for treatment intensification were 0.93 for SGLT2is, 0.77 for DPP-4is, and 0.84 for SUs, all indicating a statistically significant difference.
- After 12 months, patients on GLP-1RAs experienced a significantly greater reduction in glycated hemoglobin levels compared to those on SGLT2is, DPP-4is, and SUs.
- GLP-1RA treatment also led to significantly greater reductions in body mass index after 12 months compared to DPP-4is and SUs, though not compared to SGLT2is.
AI simplified
Key numbers
0.77
Lower Rate of
Hazard ratio for with vs.
31.4%
Weight Loss ≥ 5%
Percentage of participants with ≥ 5% weight loss after 12 months
46.6%
Glycemic Control Improvement
Proportion of patients achieving HbA < 7% after 12 months